20:30 , Oct 12, 2018 |  BioCentury  |  Emerging Company Profile

Targeting GPCRs, Ab Initio

Ab Initio Biotherapeutics Inc. is using its biochemistry expertise and an integrated set of three platforms to purify GPCRs in clinically relevant conformations for producing anti-GPCR antibodies. Antibodies can act on their targets with better...
08:00 , Dec 15, 2014 |  BioCentury  |  Emerging Company Profile

Going native

Calixar S.A.S. has developed a technology for isolating membrane proteins that preserves native conformation by using a range of novel and off-the-shelf surfactants and detergents in a target-specific fashion. According to Calixar, the platform should...